GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.
<h4>Background</h4>Parkinson's disease (PD) is a progressive multifactorial neurodegenerative condition. Epidemiological studies have shown that patients with type 2 diabetes mellitus (T2DM2) are at increased risk for developing PD, indicating a possible insulin-modulating role in t...
Guardado en:
Autores principales: | Carolina Vaccari, Denise Grotto, Tiago da V Pereira, João Lauro V de Camargo, Luciane C Lopes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/774b2b49558440bd8c5e3a01d6fb94d5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019) -
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021) -
Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Ben Jones, et al.
Publicado: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee&nbsp;W Chia, et al.
Publicado: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)